Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

359
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
359
Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer: A Post Hoc Analysis of the TOPAZ-1 Randomized Clinical Trial.

JAMA oncology·2026
Same author

Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: primary results from the phase IIIb TOURMALINE study.

Journal of hepatology·2026
Same author

A Serum lncRNA Signature Determines Oncogenic YAP Activity in Cancer Patients.

International journal of cancer·2026
Same author

Trends in the incidence and surgical treatment of hepatocellular carcinoma in Ontario.

Canadian journal of surgery. Journal canadien de chirurgie·2026
Same author

Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: The IKF-t006/IMMUNIB translational phase-2 study.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.

Nature reviews. Clinical oncology·2026

Video Experimental Relacionado

Updated: Jan 13, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.4K

Navegando la terapia de segunda línea después de la inmunoterapia en CCH avanzado

Arndt Vogel1,2,3, Anna Saborowski1, Lorenza Rimassa4,5

  • 1Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany.

JHEP reports : innovation in hepatology
|January 8, 2026
PubMed
Resumen

Los tratamientos sistémicos para el carcinoma hepatocelular han avanzado, pero la secuenciación óptima después de la terapia inicial sigue sin estar clara. Esta revisión examina la evidencia actual y las estrategias emergentes para tratamientos de segunda línea y posteriores.

Palabras clave:
inhibidor de puntos de controlcarcinoma hepatocelularterapias intraarterialesterapias locales regionalesterapia sistémicainhibidor de la tirosina quinasa

Más Videos Relacionados

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.1K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.9K

Videos de Experimentos Relacionados

Last Updated: Jan 13, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.4K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.1K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.9K

Área de la Ciencia:

  • Cánceres hepatobiliares
  • Oncología médica
  • Investigación clínica

Sus antecedentes:

  • Las opciones de tratamiento sistémico para el carcinoma hepatocelular (CCH) han mejorado significativamente los resultados de supervivencia.
  • Los avances recientes se centran principalmente en las terapias de primera línea, lo que crea desafíos para la secuenciación del tratamiento posterior.
  • Existen comparaciones directas limitadas para las terapias de CCH de segunda y posteriores líneas.

Objetivo del estudio:

  • Revisar la evidencia actual para terapias de segunda línea y posteriores en CCH.
  • Explorar consideraciones clave en la optimización de las secuencias de tratamiento para CCH.
  • Destacar las estrategias emergentes en el manejo del CCH.

Principales métodos:

  • Revisión de ensayos pivotales de fase III y estudios de fase II.
  • Análisis de datos post hoc y evidencia del mundo real.
  • Consideración de factores de la práctica clínica e investigación en curso.

Principales resultados:

  • Se han observado mejoras significativas en la supervivencia y la respuesta con terapias sistémicas avanzadas.
  • La evidencia para el tratamiento de segunda línea del CCH se deriva en gran medida de estudios no comparativos.
  • Las decisiones de tratamiento implican la integración de la evidencia con factores específicos del paciente.

Conclusiones:

  • La secuenciación óptima de las terapias después de la progresión del CCH requiere una mayor investigación.
  • Las estrategias emergentes como la continuación de la inmunoterapia y los nuevos agentes dirigidos muestran promesa.
  • El refinamiento del panorama terapéutico para el CCH requiere investigación continua y generación de evidencia.